BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37998793)

  • 41. Potentiation of Antibiotic Activity of Aztreonam against Metallo-β-Lactamase-Producing Multidrug-Resistant
    Lee S; Lee T; Kim MK; Ahn JH; Jeong S; Park KH; Chong Y
    Pharmaceutics; 2024 Jan; 16(2):. PubMed ID: 38399246
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Activity of aztreonam in combination with novel β-lactamase inhibitors against metallo-β-lactamase-producing Enterobacterales from Spain.
    Vázquez-Ucha JC; Alonso-Garcia I; Guijarro-Sánchez P; Lasarte-Monterrubio C; Álvarez-Fraga L; Cendón-Esteve A; Outeda M; Maceiras R; Peña-Escolano A; Martínez-Guitián M; Arca-Suárez J; Bou G; Beceiro A;
    Int J Antimicrob Agents; 2023 Apr; 61(4):106738. PubMed ID: 36736925
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Genetic Features Leading to Reduced Susceptibility to Aztreonam-Avibactam among Metallo-β-Lactamase-Producing Escherichia coli Isolates.
    Sadek M; Juhas M; Poirel L; Nordmann P
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32988825
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of the MTS™ aztreonam-avibactam strip (Liofilchem) on New Delhi metallo-β-lactamase-producing Enterobacterales.
    Emilie CM; Alice CM; Marine G; Farfour E; Pourbaix A; Dortet L; Lucie L; Marc V
    Eur J Clin Microbiol Infect Dis; 2024 Apr; 43(4):777-784. PubMed ID: 38277033
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vitro activity of aztreonam-avibactam against metallo-β-lactamase-producing Enterobacteriaceae-A multicenter study in China.
    Zhang B; Zhu Z; Jia W; Qu F; Huang B; Shan B; Yu H; Tang Y; Chen L; Du H
    Int J Infect Dis; 2020 Aug; 97():11-18. PubMed ID: 32473388
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vitro activity of ceftazidime/avibactam and comparators against carbapenemase-producing Enterobacterales and Pseudomonas aeruginosa isolates collected globally between 2016 and 2018.
    Kiratisin P; Kazmierczak K; Stone GG
    J Glob Antimicrob Resist; 2021 Dec; 27():132-141. PubMed ID: 34478880
    [TBL] [Abstract][Full Text] [Related]  

  • 47.
    Karlowsky JA; Bouchillon SK; El Mahdy Kotb R; Mohamed N; Stone GG; Sahm DF
    JAC Antimicrob Resist; 2021 Jun; 3(2):dlab067. PubMed ID: 34223129
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rapid Aztreonam/Avibactam NP test for detection of aztreonam/avibactam susceptibility/resistance in Enterobacterales.
    Viguier C; Bouvier M; Sadek M; Kerbol A; Poirel L; Nordmann P
    J Clin Microbiol; 2023 Oct; 61(10):e0058823. PubMed ID: 37791761
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Incidence of ESBLs and carbapenemases among Enterobacterales and carbapenemases in Pseudomonas aeruginosa isolates collected globally: results from ATLAS 2017-2019.
    Gales AC; Stone G; Sahm DF; Wise MG; Utt E
    J Antimicrob Chemother; 2023 Jul; 78(7):1606-1615. PubMed ID: 37161662
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro activity of ceftazidime-avibactam against Gram-negative strains in patients with complicated urinary tract infection and complicated intra-abdominal infection in Colombia 2014-2018.
    Lemos-Luengas EV; Rentería-Valoyes S; Cárdenas-Isaza P; Ramos-Castaneda JA
    Braz J Infect Dis; 2022; 26(3):102369. PubMed ID: 35618040
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Last resort beta-lactam antibiotics for treatment of New-Delhi Metallo-Beta-Lactamase producing Enterobacterales and other Difficult-to-Treat Resistance in Gram-negative bacteria: A real-life study.
    Larcher R; Laffont-Lozes P; Roger C; Doncesco R; Groul-Viaud C; Martin A; Loubet P; Lavigne JP; Pantel A; Sotto A
    Front Cell Infect Microbiol; 2022; 12():1048633. PubMed ID: 36544909
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of the Recent Clinical and Laboratory Standards Institute Breakpoint Changes on the Antimicrobial Spectrum of Aminoglycosides and the Activity of Plazomicin Against Multidrug-Resistant and Carbapenem-Resistant Enterobacterales From United States Medical Centers.
    Sader HS; Mendes RE; Kimbrough JH; Kantro V; Castanheira M
    Open Forum Infect Dis; 2023 Feb; 10(2):ofad058. PubMed ID: 36861086
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of Susceptibility Testing Methods for Aztreonam and Ceftazidime-Avibactam Combination Therapy on Extensively Drug-Resistant Gram-Negative Organisms.
    Khan A; Erickson SG; Pettaway C; Arias CA; Miller WR; Bhatti MM
    Antimicrob Agents Chemother; 2021 Oct; 65(11):e0084621. PubMed ID: 34424044
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Revival of Aztreonam in Combination with Avibactam against Metallo-β-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases.
    Mauri C; Maraolo AE; Di Bella S; Luzzaro F; Principe L
    Antibiotics (Basel); 2021 Aug; 10(8):. PubMed ID: 34439062
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ceftazidime-avibactam, meropenen-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo-β-lactamase-producing Klebsiella pneumoniae.
    Maraki S; Mavromanolaki VE; Moraitis P; Stafylaki D; Kasimati A; Magkafouraki E; Scoulica E
    Eur J Clin Microbiol Infect Dis; 2021 Aug; 40(8):1755-1759. PubMed ID: 33595756
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ceftibuten-Ledaborbactam Activity against Multidrug-Resistant and Extended-Spectrum-β-Lactamase-Positive Clinical Isolates of
    Karlowsky JA; Wise MG; Hackel MA; Pevear DC; Moeck G; Sahm DF
    Antimicrob Agents Chemother; 2022 Nov; 66(11):e0093422. PubMed ID: 36286518
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Assessment of Ceftazidime-Avibactam 30/20-μg Disk, Etest versus Broth Microdilution Results When Tested against
    Han R; Yang X; Yang Y; Guo Y; Yin D; Ding L; Wu S; Zhu D; Hu F
    Microbiol Spectr; 2022 Feb; 10(1):e0109221. PubMed ID: 35019685
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Geographic patterns of global isolates of carbapenem-resistant Klebsiella pneumoniae and the activity of ceftazidime/avibactam, meropenem/vaborbactam, and comparators against these isolates: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2020.
    Lee YL; Ko WC; Hsueh PR
    Int J Antimicrob Agents; 2022; 60(5-6):106679. PubMed ID: 36241011
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Implementation of Chromatic Super CAZ/AVI
    Bianco G; Boattini M; Comini S; Leone A; Bondi A; Zaccaria T; Cavallo R; Costa C
    Eur J Clin Microbiol Infect Dis; 2022 Sep; 41(9):1165-1171. PubMed ID: 35933457
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant
    Shortridge D; Kantro V; Castanheira M
    Microbiol Spectr; 2023 Feb; 11(1):e0450722. PubMed ID: 36622238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.